These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31388632)

  • 41. Retreatment of Hepatitis C Infection With Direct-Acting Antivirals.
    Segarra-Newnham M; See N; Fox-Seaman G
    Fed Pract; 2020 Jul; 37(7):316-319. PubMed ID: 32908335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.
    Lim N; Singh D; Jackson S; Lake JR
    Gastrointest Tumors; 2020 Oct; 7(4):134-143. PubMed ID: 33173777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Su F; Beste LA; Green PK; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
    Honma Y; Shibata M; Morino K; Koya Y; Hayashi T; Ogino N; Kusanaga M; Oe S; Miyagawa K; Abe S; Tabaru A; Harada M
    Dig Dis Sci; 2023 Feb; 68(2):685-698. PubMed ID: 36100828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Impact of a Sustained Virologic Response to Hepatitis C Virus Treatment on Liver Stiffness in the Puerto Rico Veterans Attending Liver Clinics in the Veterans Affairs Caribbean Healthcare System.
    Rabell-Bernal A; López-Valle R; Morales-Santiago A; Toro DH
    P R Health Sci J; 2022 Sep; 41(3):123-127. PubMed ID: 36018739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C.
    Lu M; Salgia R; Li J; Trudeau S; Rupp LB; Wu T; Daida YG; Schmidt MA; Gordon SC
    J Viral Hepat; 2023 Sep; 30(9):746-755. PubMed ID: 37415492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.
    Toyoda H; Atsukawa M; Uojima H; Nozaki A; Tamai H; Takaguchi K; Fujioka S; Nakamuta M; Tada T; Yasuda S; Chuma M; Senoh T; Tsutsui A; Yamashita N; Hiraoka A; Michitaka K; Shima T; Akahane T; Itobayashi E; Watanabe T; Ikeda H; Iio E; Fukunishi S; Asano T; Tachi Y; Ikegami T; Tsuji K; Abe H; Kato K; Mikami S; Okubo H; Shimada N; Ishikawa T; Matsumoto Y; Itokawa N; Arai T; Tsubota A; Iwakiri K; Tanaka Y; Kumada T
    Open Forum Infect Dis; 2019 May; 6(5):ofz185. PubMed ID: 31123693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of postoperative outcomes in cases achieving sustained virological response with direct-acting antiviral and interferon therapy.
    Hashimoto M; Kobayashi T; Ohira M; Okimoto S; Abe T; Inoue M; Onoe T; Honmyo N; Kuroda S; Ohdan H
    J Hepatobiliary Pancreat Sci; 2024 May; 31(5):318-328. PubMed ID: 38135908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
    J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
    Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
    Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
    Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals.
    Lee HW; Han DH; Shin HJ; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33217965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
    Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
    Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.
    Jeong D; Wong S; Karim ME; Manges AR; Makuza JD; Bartlett SR; Velásquez García HA; Luster D; Adu PA; Binka M; Yu A; Krajden M; Janjua NZ
    Lancet Reg Health Am; 2024 Jan; 29():100658. PubMed ID: 38235369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.